Search Within

Neal Rosen

Formats
  1. Journal Article (226)
  2. Meeting Abstract (186)
  3. Conference Paper (7)
  4. Book Section (2)
  5. Editorial (2)
  6. Review (2)
  7. Research Letter (1)
Groups
  1. Breast Medicine Service (426)
  2. Department of Medicine (426)
  3. GSK Faculty (426)
  4. Molecular Pharmacology and Chemistry Program Faculty (426)
  5. Sloan Kettering Institute Faculty (426)
  6. Solid Tumor Oncology Division (426)

More Groups

People
  1. David Solit (155)
  2. Sarat Chandarlapaty (57)
  3. Howard Scher (44)
  4. Christine Pratilas (36)
  5. Elisa De Stanchina (36)
  6. Laura Sepp-Lorenzino (36)

More People

Years
  1. 2025 (2)
  2. 2024 (6)
  3. 2023 (2)
  4. 2022 (13)
  5. 2021 (13)
  6. 2020 (12)

More Years

Publications
  1. Cancer Research (99)
  2. Clinical Cancer Research (43)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (36)
  4. Cancer Discovery (24)
  5. Journal of Clinical Oncology (23)
  6. Cancer Cell (15)

More Publications

Publishers
  1. American Association for Cancer Research (212)
  2. Nature Publishing Group (38)
  3. American Society of Clinical Oncology (24)
  4. Cell Press (19)
  5. Elsevier Inc. (17)
  6. National Academy of Sciences (11)

More Publishers

Results (426)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SNX5542, an oral Hsp90 inhibitor, causes Her2 degradation and inhibition of tumor growth in models of Her2 amplified breast cancer
    Meeting Abstract

    Chandarlapaty, S.; Ye, Q.; Huang, K.; Fadden, P.; Rosen, N.; Solit, D.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Antimyeloma activity of heat shock protein-90 inhibition
    Journal Article

    Mitsiades, C. S.; Mitsiades, N. S.; McMullan, C. J.; Poulaki, V.; Kung, A. L.; Davies, F. E.; Morgan, G.; Akiyama, M.; Shringarpure, R.; Munshi, N. C.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors
    Journal Article

    Yang, S.; Qu, S.; Perez-Tores, M.; Sawai, A.; Rosen, N.; Solit, D. B.; Arteaga, C. L.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Hsp90: A novel target for cancer therapy
    Journal Article

    Solit, D. B.; Rosen, N.
    Current Topics in Medicinal Chemistry (2006)

    Fulltext@MSK | Save
  • BRAF mutation predicts sensitivity to MEK inhibition
    Journal Article

    Solit, D. B.; Garraway, L. A.; Pratilas, C. A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J. M.; She, Y.; Osman, I.; more...
    Nature (2006)

    Fulltext@MSK | Save
  • Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET
    Journal Article

    Smith-Jones, P. M.; Solit, D.; Afroze, F.; Rosen, N.; Larson, S. M.
    Journal of Nuclear Medicine (2006)

    Fulltext@MSK | Save
  • AKT and cancer-Is it all mTOR?
    Journal Article

    Rosen, N.; She, Q. B.
    Cancer Cell (2006)

    Fulltext@MSK | Save
  • mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
    Journal Article

    O'reilly, K. E.; Rojo, F.; She, Q. B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; more...
    Cancer Research (2006)

    Fulltext@MSK | Save
  • V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
    Journal Article

    Grbovic, O. M.; Basso, A. D.; Sawai, A.; Ye, Q.; Friedlander, P.; Solit, D.; Rosen, N.
    Proceedings of the National Academy of Sciences of the United States of America (2006)

    Fulltext@MSK | Save
  • Combined inhibition of PI3 kinase and EGFR overcomes the intrinsic apoptosis resistance of PTEN-null cancer cells and suppresses their xenograft growth
    Meeting Abstract

    She, Q. B.; Solit, D.; Ye, Q.; O'reilly, K.; Rosen, N.
    Cancer Research (2005)

    Fulltext@MSK | Save